Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Lisa D Earnhardt. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Lisa D Earnhardt har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ABT / Abbott Laboratories | EVP AND GROUP PRESIDENT | 71 928 |
US:XENT / Intersect ENT Inc | Director | 48 333 |
US:NVRO / Nevro Corp. | Director | 5 303 |
US:KNSY / Kensey Nash Corp | Director | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Lisa D Earnhardt. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Lisa D Earnhardt som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 71 928 | −0,28 | 136,64 | −27 329 | 9 828 602 | |
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 200 | 72 128 | 0,28 | 80,98 | 16 196 | 5 840 925 | |
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −91 167 | 71 928 | −55,90 | 133,82 | −12 199 968 | 9 625 405 | |
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 91 167 | 163 095 | 126,75 | 80,98 | 7 382 704 | 13 207 433 | |
2025-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −8 322 | 71 928 | −10,37 | 135,87 | −1 130 710 | 9 772 857 | |
2025-02-27 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 18 788 | 80 250 | 30,57 | ||||
2024-05-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −22 852 | 61 462 | −27,10 | 106,25 | −2 428 119 | 6 530 589 | |
2024-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −694 | 84 314 | −0,82 | 118,50 | −82 239 | 9 991 209 | |
2024-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −7 669 | 85 008 | −8,27 | 120,05 | −920 663 | 10 205 210 | |
2024-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 17 240 | 92 677 | 22,85 | ||||
2023-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −943 | 75 437 | −1,23 | 100,70 | −94 960 | 7 596 506 | |
2023-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −7 631 | 76 380 | −9,08 | 99,77 | −761 345 | 7 620 433 | |
2023-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 15 855 | 84 011 | 23,26 | ||||
2022-06-14 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −19 592 | 68 156 | −22,33 | 112,71 | −2 208 214 | 7 681 863 | |
2022-06-14 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 882 | 87 748 | −3,18 | 112,71 | −324 830 | 9 890 077 | |
2022-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −943 | 90 630 | −1,03 | 118,15 | −111 416 | 10 707 962 | |
2022-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −5 168 | 91 573 | −5,34 | 122,41 | −632 615 | 11 209 451 | |
2022-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 80 380 | 80 380 | |||||
2022-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 17 247 | 96 741 | 21,70 | ||||
2021-06-11 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 881 | 79 494 | −3,50 | 109,05 | −314 173 | 8 668 821 | |
2021-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −943 | 82 375 | −1,13 | 120,61 | −113 735 | 9 935 249 | |
2021-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 621 | 83 318 | −3,05 | 121,58 | −318 661 | 10 129 802 | |
2021-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 71 070 | 71 070 | |||||
2021-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 13 865 | 85 939 | 19,24 | ||||
2020-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −872 | 72 074 | −1,20 | 90,84 | −79 216 | 6 547 490 | |
2020-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 855 | 72 946 | −3,77 | 90,27 | −257 721 | 6 584 835 | |
2020-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 114 940 | 114 940 | |||||
2020-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 18 855 | 75 801 | 33,11 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 48 333 | 48 333 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −48 333 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 45 500 | 45 500 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −45 500 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 196 875 | 196 875 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −196 875 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 150 000 | 150 000 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −150 000 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
A - Award | 19 688 | 19 688 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | −19 688 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 44 625 | 44 625 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −44 625 | 0 | −100,00 | ||||
2019-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 91 367 | 91 367 | |||||
2019-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 39 515 | 56 946 | 226,69 | ||||
2019-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 17 431 | 17 431 | |||||
2019-06-12 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
0 | ||||||||
2019-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −9 500 | 140 000 | −6,35 | ||||
2019-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −9 500 | 421 983 | −2,20 | 25,59 | −243 102 | 10 798 418 |
2019-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 9 500 | 431 483 | 2,25 | 13,05 | 123 975 | 5 630 853 | |
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −6 016 | 48 333 | −11,07 | ||||
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −7 500 | 149 500 | −4,78 | ||||
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −29 588 | 421 983 | −6,55 | 28,43 | −841 243 | 11 997 778 |
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 6 016 | 451 571 | 1,35 | 1,20 | 7 219 | 541 885 | |
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 7 500 | 445 555 | 1,71 | 13,05 | 97 875 | 5 814 493 | |
2019-01-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
A - Award | 157 500 | 157 500 | |||||
2019-01-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
A - Award | 33 800 | 438 055 | 8,36 | ||||
2019-01-03 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
F - Taxes | −10 428 | 404 255 | −2,51 | 26,57 | −277 046 | 10 740 045 | |
2018-12-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −35 000 | 54 349 | −39,17 | ||||
2018-12-26 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 35 000 | 414 683 | 9,22 | 1,20 | 42 000 | 497 620 | |
2018-12-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 157 000 | −3,09 | ||||
2018-12-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 379 683 | −5,00 | 29,73 | −594 504 | 11 286 153 |
2018-12-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 399 683 | 1,27 | 13,05 | 65 250 | 5 215 863 | |
2018-11-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 162 000 | −2,99 | ||||
2018-11-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 394 683 | −4,82 | 30,01 | −600 296 | 11 846 331 |
2018-11-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 414 683 | 1,22 | 13,05 | 65 250 | 5 411 613 | |
2018-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 167 000 | −2,91 | ||||
2018-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 409 683 | −4,65 | 29,63 | −592 614 | 12 139 194 |
2018-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 429 683 | 1,18 | 13,05 | 65 250 | 5 607 363 | |
2018-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 172 000 | −2,82 | ||||
2018-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 424 683 | −4,50 | 29,14 | −582 862 | 12 376 579 |
2018-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 444 683 | 1,14 | 13,05 | 65 250 | 5 803 113 | |
2018-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 177 000 | −2,75 | ||||
2018-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 439 683 | −4,35 | 26,51 | −530 194 | 11 655 864 |
2018-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 459 683 | 1,10 | 13,05 | 65 250 | 5 998 863 | |
2018-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 182 000 | −2,67 | ||||
2018-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 454 683 | −4,21 | 33,08 | −661 686 | 15 042 869 |
2018-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 474 683 | 1,06 | 13,05 | 65 250 | 6 194 613 | |
2018-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 187 000 | −2,60 | ||||
2018-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 469 683 | −4,08 | 36,79 | −735 710 | 17 277 524 |
2018-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 489 683 | 1,03 | 13,05 | 65 250 | 6 390 363 | |
2018-05-23 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 3 785 | 5 303 | 249,34 | ||||
2018-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 192 000 | −7,25 | ||||
2018-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 39,22 | −588 244 | 19 007 474 |
2018-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 207 000 | −6,76 | ||||
2018-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 39,59 | −593 918 | 19 190 781 |
2018-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 222 000 | −6,33 | ||||
2018-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 38,32 | −574 791 | 18 572 762 |
2018-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-02-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 237 000 | −5,95 | ||||
2018-02-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 36,40 | −545 938 | 17 640 474 |
2018-02-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-01-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −11 166 | 484 683 | −2,25 | 33,47 | −373 695 | 16 220 983 |
2018-01-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
A - Award | 119 000 | 119 000 | |||||
2018-01-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
A - Award | 25 500 | 495 849 | 5,42 | ||||
2018-01-03 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
F - Taxes | −6 834 | 470 349 | −1,43 | 33,93 | −231 897 | 15 960 259 | |
2017-12-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −2 000 | 6 016 | −24,95 | ||||
2017-12-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −10 685 | 477 183 | −2,19 | 31,87 | −340 512 | 15 206 963 |
2017-12-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 2 000 | 487 868 | 0,41 | 1,20 | 2 400 | 585 442 | |
2017-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 8 016 | −55,51 | ||||
2017-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 485 868 | −3,95 | 27,88 | −557 620 | 13 546 486 |
2017-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 505 868 | 2,02 | 1,20 | 12 000 | 607 042 | |
2017-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 18 016 | −35,69 | ||||
2017-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 495 868 | −3,88 | 28,37 | −567 336 | 14 066 188 |
2017-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 515 868 | 1,98 | 1,20 | 12 000 | 619 042 | |
2017-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 28 016 | −26,30 | ||||
2017-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 505 868 | −3,80 | 30,19 | −603 870 | 15 273 925 |
2017-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 525 868 | 1,94 | 1,20 | 12 000 | 631 042 | |
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 38 016 | −20,83 | ||||
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 515 868 | −3,73 | 30,79 | −615 810 | 15 883 834 |
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 535 868 | 1,90 | 1,20 | 12 000 | 643 042 | |
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
G - Gift | −35 000 | 525 868 | −6,24 | ||||
2017-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 48 016 | −17,24 | ||||
2017-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 560 868 | −3,44 | 29,03 | −580 642 | 16 283 176 |
2017-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 580 868 | 1,75 | 1,20 | 12 000 | 697 042 | |
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −2 625 | 58 016 | −4,33 | ||||
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −7 375 | 0 | −100,00 | ||||
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 570 868 | −3,38 | 26,10 | −521 978 | 14 899 027 |
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 7 375 | 590 868 | 1,26 | 1,20 | 8 850 | 709 042 | |
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 2 625 | 583 493 | 0,45 | 1,20 | 3 150 | 700 192 | |
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 545 | 3 545 | |||||
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 1 518 | 1 518 | |||||
2017-05-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 7 375 | −57,55 | ||||
2017-05-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 580 868 | −3,33 | 22,98 | −459 520 | 13 346 023 |
2017-05-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 600 868 | 1,69 | 1,20 | 12 000 | 721 042 | |
2017-04-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 17 375 | −36,53 | ||||
2017-04-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 590 868 | −3,27 | 16,06 | −321 244 | 9 490 640 |
2017-04-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 610 868 | 1,66 | 1,20 | 12 000 | 733 042 | |
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 27 375 | −26,76 | ||||
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −10 000 | 600 868 | −1,64 | 15,02 | −150 188 | 9 024 316 |
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −10 000 | 610 868 | −1,61 | 15,03 | −150 265 | 9 179 208 |
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 620 868 | 1,64 | 1,20 | 12 000 | 745 042 | |
2017-02-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −20 000 | 37 375 | −34,86 | ||||
2017-02-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 610 868 | −3,17 | 13,01 | −260 170 | 7 946 476 |
2017-02-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 20 000 | 630 868 | 3,27 | 1,20 | 24 000 | 757 042 | |
2017-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
A - Award | 252 000 | 252 000 | |||||
2017-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
A - Award | 54 000 | 610 868 | 9,70 | ||||
2016-10-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
M - Exercise | −400 | 56 975 | −0,70 | ||||
2016-10-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −400 | 556 868 | −0,07 | 18,00 | −7 200 | 10 023 624 |
2016-10-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 400 | 557 268 | 0,07 | 1,20 | 480 | 668 722 | |
2016-05-20 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 240 | 3 240 | |||||
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −4 000 | 57 375 | −6,52 | ||||
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −8 500 | 556 868 | −1,50 | 19,50 | −165 740 | 10 858 258 |
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 4 000 | 565 368 | 0,71 | 1,20 | 4 800 | 678 442 | |
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −20 000 | 61 375 | −24,58 | ||||
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 561 368 | −3,44 | 18,34 | −366 848 | 10 296 836 |
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 20 000 | 581 368 | 3,56 | 1,20 | 24 000 | 697 642 | |
2016-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −9 000 | 561 368 | −1,58 | 18,01 | −162 084 | 10 109 845 |
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
A - Award | 225 000 | 225 000 | |||||
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −8 000 | 81 375 | −8,95 | ||||
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −12 500 | 570 368 | −2,14 | 19,26 | −240 808 | 10 987 911 |
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 8 000 | 582 868 | 1,39 | 1,20 | 9 600 | 699 442 | |
2015-12-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 820 | 574 868 | −1,17 | 19,85 | −135 408 | 11 413 717 |
2015-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 581 688 | −1,16 | 18,00 | −122 732 | 10 471 082 |
2015-10-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 588 506 | −1,15 | 18,72 | −127 619 | 11 015 655 |
2015-09-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 595 324 | −1,13 | 25,99 | −177 229 | 15 475 031 |
2015-08-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 602 142 | −1,12 | 28,51 | −194 385 | 17 167 369 |
2015-07-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 608 960 | −3,07 | 29,62 | −572 153 | 18 035 934 |
2015-07-01 |
|
4 | NVRO |
NEVRO CORP
Stock Option (right to buy) |
A - Award | 5 853 | 5 853 | |||||
2015-06-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 628 278 | −2,98 | 29,30 | −565 992 | 18 407 729 |
2015-05-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 647 596 | −2,90 | 23,69 | −457 628 | 15 341 031 |
2015-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 666 914 | −2,82 | 25,96 | −501 544 | 17 314 755 |
2015-03-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 686 232 | −2,74 | 23,56 | −455 057 | 16 164 950 |
2015-02-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 705 550 | −2,67 | 22,69 | −438 343 | 16 009 564 |
2015-01-23 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
A - Award | 150 000 | 150 000 | |||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
1 475 918 | ||||||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
777 232 | ||||||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
1 475 918 | ||||||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
777 232 | ||||||||
2012-06-26 |
|
4 | KNSY |
KENSEY NASH CORP
Common Stock |
D - Sale to Issuer | −5 100 | 0 | −100,00 | 38,50 | −196 350 |